Today's Peptide News — October 2, 2026

A UC San Diego School of Medicine team reported in Molecular Therapy (published September 22, 2026) that catestatin, a naturally occurring fragment of chromogranin A, reduced abnormal tau and amyloid accumulation, lowered brain inflammation, and improved cognitive and motor function in mouse models of neurodegeneration. Note: this is about ten days old, the freshest peptide paper the search turned up.

Why it matters: most Alzheimer's candidates hit one target. Senior researcher Sushil K. Mahata says catestatin acts across several disease-associated pathways at once, shifting the brain toward a healthier state. The work is preclinical, and safety, dosing and efficacy studies are needed before any human trial.

Suggested PeptideWiki angle: a short explainer on catestatin as an endogenous multi-pathway peptide, covering what it is, where it comes from (chromogranin A), the mouse findings, and a clear preclinical caveat.

In late July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention in favor of adding BPC-157 (for ulcerative colitis) and KPV (for wounds and inflammatory conditions) to the 503A bulks list. TB-500, MOTS-C, emideltide, epitalon and semax were also under consideration at the same two-day meeting. Note: this is background from July, not a development from the last 24 hours; I found no newer update.

The vote could let state-licensed compounding pharmacies prepare these peptides for individual patients, though FDA staff had recommended against it, citing lack of evidence of effectiveness for BPC-157 and that it is not well characterized. The FDA still has to act on the recommendations.

A September 30 report says about 700,000 seniors have started GLP-1 obesity treatment since Medicare's Bridge program launched July 1, 2026, roughly 70% of them on Eli Lilly products, with a $50 monthly copay. AstraZeneca's once-daily oral elecoglipron is now in Phase 3, with Phase 2 results of 11.8% average weight loss at 36 weeks and a 1.9-point HbA1c reduction.

Elecoglipron is a small molecule, not a peptide, which is the same distinction made for Lilly's orforglipron (Foundayo), approved in April 2026. The Bridge program runs through December 31, 2027, so approval timing may fall after it ends.

ScienceDaily reports on October 1 that following the MIND diet was linked to roughly 2.5 years of delayed brain aging, driven by reduced gray matter loss. The summary available to me was brief, so check the source for study design and caveats.

Mount Sinai researchers report that the Alzheimer's risk gene APOE4 turns blood-vessel support cells (pericytes) into scar-producing cells, promoting fibrosis and amyloid buildup, and that blocking TGF-beta signaling reversed this in lab models and aged mice (Cell, September 24, 2026).

A companion Cell Stem Cell study found APOE4 causes cholesterol buildup in astrocytes, letting alpha-synuclein accumulate. Both used stem-cell-derived 3D human brain tissue called miBrains.

Research reported September 29 shows creatine supplementation improved muscle strength and lean tissue mass in sedentary adults even without resistance training, with exploratory hints of cognitive benefit.

A Nature Communications study found coffee influences gut microbiota and cognition. Both caffeinated and decaffeinated drinkers reported lower stress, depression and impulsivity scores, with decaf showing a memory benefit.